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Contact dermatitis is an inflammatory response ofthe
skin characterized by dermal perivascular and epider-
mal mononuclearjiell infiltration, spongiosis, and hy-
perplasia. Often a reslilt of insult by antigen or irritant,
it is caused by an upset in the normal balance of im-
munoregulatory signals from both resident and non-
resident cells. T cells, which continuously traffic
through the skin, are central to the skin's immunore-
gulation. Their activation and subsequent lymphokine
release are critical events in the development of an
inflammatory immune reaction.
Activation of T lymphocytes can occur via either
antigen-dependent or antigen-independent pathways.
Antigen-dependent recognition is critical to allergic
contact dermatitis reactions, whereas antigen-indepen-
dent pathways seem important in irritant-induced
contact dermatitis. Langerhans cells are the only anti-
gen-presenting cells constitutively found in the epi-
dermis. They present antigen to T cells, thereby elicit-
ing T-cell activation and providing positive signals for
upregulation of the immune response. Conversely,
other epidermal antigen-presenting cell (APC) sub-
types that migrate into the epidermis during an allergic
contact dermatitis reaction may activate suppressor
pathways, thus downregulating the immune reaction.
Keratinocytes, which comprise approximately 90% of
the total epidermal cell population, are not passive
bystanders in the immune response and can transmit
both positive and negative signals. Thus, they may
function as a modulator ofthe immune system, up- or
downregulating T-cell responses. Injury- or irritant-ac-
tivated keratinocytes can elaborate factors and cyto-
kines that may be responsible for antigen-independent
T-cell activation and lymphokine release resulting in
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an inflammatory skin reaction. The cellular interac-
tions and the mechanisms that govern them in the
development of both allergic and irritant contact der-
matitis form the focus of this review.
Epidermal immunocompetent Ceils
To understand the pathogenetic mechanisms involved
in contact dermatitis, it is important to appreciate the
different immunocompetent cells ofthe skin. The epi-
dermis represents the outermost boundary of the im-
mune system and is composed mainly of keratino-
cytes, Langerhans cells, and melanocytes. Keratino-
cytes and Langerhans cells are known to be
immunocompetent; however, the immunologic func-
tion of melanocytes, if any, is not clear.
The keratinocyte's role in the immunoregulation
ofthe skin has only recently been appreciated. The first
indication of its immunocompetent nature was the
unexpected discovery in the early 1980s by Luger et al.
and Sauder et al. of a keratinocyte-derived cytokine,
epidermal cell-derived thymocyte activating factor
(ETAF).'- The majority of ETAF activity was later
found to be due to interleukin-1 (IL-1). As keratino-
cytes were investigated more widely, it became clear
that activated keratinocytes have the ability to produce
a variety of distinct T-cell-activating and growth-stim-
ulating cytokines.^" Others include interleukin-3
(IL-3),^''' granulocyte macrophage colony stimulating
factor (GM-CSF),^ epidermal cell-derived natural
killer cell activating factor (ENKAF),** and interleu-
kin-6 (IL-e).*^
In addition to these growth-promoting and acti-
vating cytokines, keratinocytes also synthesize T-cell
inhibitory cytokines and factors. These include epider-
mal cell-derived lymphocyte differentiation inhibiting
factor,'" keratinocyte lymphocyte inhibitory factor,"'^
eicosanoids,'^"'^ IL-I inhibitor,"' and transforming
growth factor beta.'^ As well as T-cell stimulatoi-y and
inhibitory factors, keratinocytes also elaborate mono-
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nuclear cell chemotactic factors, which are not well
characterized.'^ The actions of some of these epider-
mal factors and cytokines as they may relate to contact
dermatitis are introduced briefly below.
Since its discovery, interleukin-1 has been widely
investigated. Epidermal IL-1 release can be induced by
specific stimuli, (eg, antigen'^) or by traumatic epider-
mal injury, (eg, irritant and/or ultraviolet [UV] irra-
diation""^'). Interleukin-1 can enhance an immune
response directly by inducing T-cell activation and
proliferation,^^ and indirectly by inducing the secre-
tion of GM-CSF.^' Interleukin-6 acts synergistically
with IL-1 in T-cell activation, and its release may
thereby enhance IL-1 -induced T-cell proliferation and
lymphokine release.'
In contrast to the growth stimulatory cytokines,
both ELDIF and KLIF inhibit T-cell proliferation and
IL-2 production.'°"'^ Keratinocyte lymphocyte inhibi-
tory factor may be a composite of different cytokines,
including TGF-beta, since KLIF's inhibitory effect is
partially reversible by an antibody against TGF-
beta.'^'^'' Eicosanoids, including PGE2, modulate the
interaction between T cells and antigen-presenting
cells such that suppressor/effector T cells are preferen-
tially activated.'^ Eicosanoids can also function as che-
motactic factors for T cells. Keratinocytes also elabo-
rate factors distinct from eicosanoids, IL-1, and IL-8
that are chemotactic for T cells.'^ Whether these play a
role in contact dermatitis remains to be elucidated.
Another immunocompetent epidermal cell type is
the dendritic bone marrow-derived Langerhans cell,
which comprises 2% to 5% of the total epidermal cell
population.^^ While they represent only a minority of
the epidermal cell population, they are the only consti-
tutively present antigen-presenting cell type of the
human epidermis. '̂'•^^ Suprabasally localized in the
epidermis, it was the first resident epidermal cell type
with immune function to be described. Ultrastructur-
ally, Langerhans cells are distinguished from other cell
types by their intracytoplasmic Birbeck's granules.
They express CDl, a major histocompatibility com-
plex (MHC) class I-like molecule and human leuko-
cyte antigen (HLA)-DR, an MHC class II molecule.̂ "̂̂ "
CDl may be involved in receptor-mediated endocy-
tosis, while HLA-DR is probably involved in presenta-
tion of the processed antigen to CD4^ T cells.
Dermal Immunocompetent Cells
Fibroblasts, endothelial cells, dermal antigen-present-
ing cells, mast cells, and lymphocytes are the immuno-
competent cell types of the dermis.
Structurally, the dermis consists of a framework of
collagen, elastic, and reticular fibers embedded in a
matrix of glycosaminoglycans. These elements are all
produced by the fibroblast. In addition, fibroblasts can
be stimulated by IL-1 to produce prostaglandins,
which may be involved in inflammation.-" Thus, be-
sides producing the dermal framework, fibroblasts also
may function in immune reactions.
The dermal vessels are lined by endothelial cells
that constitutively express intercellular adhesion mole-
cule-1 (ICAM-1).̂ ^ This molecule is a natural ligand
for lymphocyte function-associated antigen-1
(LFA-1 ),^^ a glycoprotein expressed on the surface of
most leukocytes. Thus, a molecule expressed by endo-
thelial cells is the natural binding site for a molecule
expressed by many leukocytes. These adhesion mole-
cules are recognized to be important for cell-cell inter-
actions; upregulation of their expression by cytokines
may be involved in the migration of leukocytes from
the vessels into the dermis and the epidermis.
Possible antigen-presenting cells of the dermis are
the dermal dendrocytes. They are HLA-DR"̂  and are
localized around the papillary vascular plexus. These
cells may be analogous to dermal Ia^ cells of the mu-
rine system, which have the capacity to present anti-
gens to T lymphocytes.̂ "*
Another dermal cell type, the mast cell, can be
stimulated by the immune system to release histamine
and platelet-activating factor.̂ '̂̂ * Histamine generates
prostaglandins, stimulates suppressor lymphocytes,
and is a potent vasoconstrictor.^ '̂̂ ^ Platelet-activating
factor is a potent stimulus for leukocyte migration and
the production of lipoxygenase products of arachi-
donic acid metabolism.•'^ These products are potent
mediators of inflammation.
The few lymphocytes present in the dermis are
mainly T cells and include virtually no B cells. These
cells are found around the postcapillary venules of the
papillary vascular plexus and most of them express
HLA-DR and IL-2 receptors, which indicates that they
are in a functionally activated state. T cells can be
divided into two functionally distinct subsets distin-
guished by their expression of the CD4 or the CD8
molecule. CD4''̂  T cells interact with MHC class II-
bearing cells (antigen-presenting cells), while CD8^ T
cells interact with MHC class I-bearing cells (all nu-
cleated cells). CD4^ T cells can be further divided into
helper/inducers, which express high levels of 4B4, and
suppressor/inducers, which express high levels of 2H4.
In normal dermis, the CD4+ and CD8"̂  T-cell subsets
are evenly distributed."" However, of the CD4^ T cells,
the majority are 434"̂  (helper/inducer T lymphocytes),
and the minority are 2H4+ (suppressor/inducer T lym-
phocytes).'*" In contrast, the CD4+2H4+ and the
CD4^4B4^ lymphocyte subpopulations in peripheral
blood are the same size.
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Activated T lymphocytes elaborate a variety of
lymphokines potentially important for contact derma-
titis reactions, including IL-2,'" gamma interferon,''^
IL-S," '̂"*" ^-4,"= and GM-CSF.'*'̂ ''̂  As stated pre-
viously, T lymphocytes can be activated through both
antigen-dependent and -independent pathways. Anti-
gen-dependent T-cell activation is critical to the initia-
tion of allergic contact hypersensitivity reactions and is
described below.
Pathogenic Mechanism of Aiiergic Contact
Dermatitis
Most allergens are low molecular weight, highly reac-
tive, lipid-soluble haptens that must be conjugated to
an epidermal carrier protein before they can function
as complete antigens. Antigen-specific activation of T
cells is critically dependent on antigen-presenting cells,
which express MHC class II molecules such as HLA-
DR or HLA-DQ. Langerhans cells, which express CD 1
and HLA-DR (ie, CDrDR+), are the only cells in
normal human epidermis capable of presenting anti-
gens to T cells. CD 1 ̂ DR^ Langerhans cells can process
and present hapten/carrier conjugates into an immu-
nogenic form recognizable by CD4^ inducer T lym-
It is thought that Langerhans cells internalize anti-
gen by pinocytosis. The pinocytotic antigen-contain-
ing vesicle then fuses with a lysosome, creating a
phagolysosome. Enzymes within the phagolysosome
partly digest the antigen into immunogenic antigen
fragments, termed processed antigen. It seems that
these combine with cytoplasmic HLA-DR molecules
and are transported to the cell surface membrane,
where they are coexpressed (Fig. 1). CD4^ T cells can-
not recognize antigen alone; only when presented in
the context of MHC class II molecules is the antigen
recognized.
The T-cell structure responsible for antigen recog-
nition is termed the T-cell receptor and consists of an
alpha/beta peptide heterodimer that is rearranged dur-
ing thymic development. Rearrangement generates a
unique antigen-specific receptor for each T-cell clone.
The signal produced in response to antigen recognition
by the T-cell receptor is transmitted to the interior of
the cell via the transduction peptide CD3, which is
complexed with the T-cell receptor. The resulting acti-
vation of the T cell causes the T cell to express IL-2
receptor on its surface and to release IL-2 and other
lymphokines. Binding of IL-2 to the IL-2 receptor in-
duces T-cell proliferation. Thus, lL-2 functions as an
autocrine T-cell growth factor. Such activation results
in the generation of effector T cells capable of mediat-
ing delayed-type hypersensitivity reactions"*^" '̂ as well
Processed Ag
Figure 1. Antigen processing and presentation. Soluble antigens (Ag)
are taken up by the Langerhans cell by pinocytosis. The internalized
antigen contained within the pinocytotic vesicle is fused with a lyso-
some (L), creating a phagolysosome (PH). Enzymes within the
phagolysosome partially digest the antigen, which is subsequently
expressed on the surface ofthe cell membrane in the context of class
II MHC molecules such as HLA-DR. The antigen/HLA-DR com-
plex will now be recognized by the T-cell receptor eliciting T-cell
activation.
as the generation of cytotoxic T cells directed against
haptenized epidermal cells.̂ "'̂ ^ However, immunoreg-
ulatory suppressor T cells that down-modulate the ef-
fector responses are also induced.^''" The net effect of
the immune response is therefore dependent on the
balance between effector and regulatory cells.
Except when very potent allergens are involved,
the primary sensitizing event does not normally result
in clinical skin lesions. This is probably due to the low
number of responder T lymphocytes present. How-
ever, subsequent rechallenges resulting in clonal T-cell
expansion and representation ofthe antigen to primed
(memory) T cells may result in cytokine release and
cytotoxicity, generating an acute contact dermatitis le-
sion. The sensitization and elicitation phases of the
immune response in allergic contact dermatitis are de-
scribed in more detail below.
Sensitization in Aiiergic Contact Dermatitis
Following sensitization in animals, Langerhans cells
have been found in the dermal lymphatics and in the
draining regional lymph nodes.^'' This may indicate
that Langerhans cells take up antigen in the skin and
migrate to the paracortical area of the regional lymph
node, where they present the processed antigen to un-
primed T cells with specificity for that particular anti-
gen.̂ ^ This results in the generation and expansion of
antigen-specific memory T cells (ie, primed T cells).
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Figure 2. Sensitization, the afferent phase of the immune response in allergic contact dermatitis.
Lipid soluble reactive haptcns applied to the skin cross the stratum corneum and bind to protein
carriers in the skin creating complete antigens. The antigen (hapten-carrier conjugate) is internal-
ized by the Langerhans cell, processed, and then expressed on the surface membrane in the context
of.class II MHC molecules. The Langerhans cell moves out of the epidermis through the afferent
draining lymphatic to the regional lymph nodes. Following Langerhans cell antigen presentation to
unprimed T cells in the paracortical area, the T cells undergo expansion then exit the node. The
primed (memory) T cells travel via the thoracic duct to the superior vena cava, are distributed
through the circulatory system, and home to the site challenged by hapten. Representation of
antigens to primed (memory) T cells can now occur and will result in amplification of the immune
response. (Reproduced with permission from Cooper K, Roitt IM, Du Vivier A, et al. Immunology
Slide Atlas. New York: Gower Medical Publishing, 1989.)
which then distribute throughout the circulation and
home to the site of antigen challenge (Fig. 2).
The Langerhans cell's role in the induction of
contact hypersensitivity is highlighted by studies per-
formed in Langerhans cell-depleted skin, such as mu-
rine tail skin, UV-irradiated skin, or in epidermal cell
suspensions depleted of Langerhans cells by UV irra-
diation. Sensitization in these systems results in the
development of antigen-specific tolerance. ̂ ~̂''° Peroral
or intravenous administration of the allergen may also
result in antigen-specific tolerance. Thus, it appears
that when antigen is presented by non-Langerhans an-
tigen-presenting cells, T suppressor lymphocytes are
activated, and tolerance, rather than contact hypersen-
sitivity, results.
Elicitation of Allergic Contact Dermatitis
Rechallenge of the skin will result in representation of
the antigen by Langerhans and possibly non-Langer-
hans antigen-presenting cells to primed T cells. This
may take place in the epidermis, the dermis, or in the
regional draining lymph nodes, and results in T-cell
activation. As stated previously, these activated T cells
release a variety of lymphokines, such as IL-2,'"
gamma-interferon,''^ GM-CSF,"'^''^ IL-3,''3''"* and
IL-4.''̂  These lymphokines have a variety of immuno-
logic effects that are potentially important in contact
dermatitis.
Gamma-interferon released from lesional acti-
vated T cells upregulates the expression of intercellular
adhesion molecules, such as ICAM-1, on both kerati-
nocytes and endothelial cells.̂ '''̂ '-^^ This is thought to
be important for the recruitment of cells that express
LFA-1, such as T cells and other leukocytes,̂ "* which
then participate in the ongoing immune response.
Interleukin-3 is present in the early phases of a
delayed-type hypersensitivity reaction^^ and is released
from activated T cells. It induces mast cell prolifera-
tion and is involved in the activation of monocytes.
No. 3 Immune Regulation in Skin Reactions • Baadsgaard and Wang 165
Mast cells and monocytes are present in increased
numbers in contact hypersensitivity reactions. Fur-
thermore, IL-3 and GM-CSF, as well as other lympho-
kines, may enhance keratinocyte proliferation.̂ "* Thus,
these activated T-cell products may be partially re-
sponsible for the epidermal hyperplasia seen in contact
dermatitis (Fig. 3).
In addition to lymphokines released by activated T
cells, other cytokines are important in the elicitation of
contact dermatitis. Interleukin-1, a cytokine released
from Langerhans cells, macrophages, and keratino-
cytes has been found in increased amounts in the epi-
dermis during an allergic patch test reaction.'^ The
binding of IL-1 to keratinocyte IL-1 receptors stimu-
lates keratinocyte growth and may thereby contribute
to the epidermal hyperplasia seen in contact hypersen-
sitivity."--^ Interleukin-1 may also stimulate keratino-
cyte release of GM-CSF, which may result in the ex-
pansion of the Langerhans cell population.^^ Indeed,
the number of Langerhans cells is increased in allergic
contact dermatitis.""*^"
In allergic skin reactions, CD1"DR^ non-Langer-
hans antigen-presenting cells appear in the epi-
dermis.̂ '- '̂''' These cells are able to activate autologous
T cells and are responsible for up to 50% of the total
epidermal T-cell activating capacity during the allergic
reaction.*** The function of these antigen-presenting
cells is unknown. However, they may be analogous to
HLA-DR
IL-2
Figure 3. Elicitation, the efferent phase of the immune response in allergic contact dermatitis.
Presentation of antigen in the skin by Langerhans and other antigen-presenting cells to primed
(memory) T cells results in T-cell activation and expansion and lymphokine release. The antigen is
presented in the context of HLA-DR class II MHC molecules to the T-cell receptor, a heterodimer
composed of an alpha and beta peptide chain. The signal is transmitted from the T-cell receptor to
the interior of the cell via a transduction peptide termed CD3. Activation causes the T cells to
release lymphokines including IL-2, IL-3, gamma-IFN and GM-CSF and to express IL-2 receptors.
IL-2 binding to the IL-2 receptor induces T-cell proliferation. IL-.3 and GM-CSF may induce
keratinocyte proliferation and may be responsible for the epidermal hyperplasia seen in contact
dermatitis. Gamma-IFN and tumor necrosis factor induce keratinocyte expression of intercellular
adhesion molecules (e.g., ICAM-1), whereas only gamma-interferon induces HLA-DR. ICAM-1 is
the natural ligand for LFA-1, a molecule expressed by many leukocytes that is important for
cell-cell interaction. ICAM-1 also may be responsible for compartmentalization of leukocytes in
the skin during a contact dermatitis reaction. Keratinocytes that express HLA-DR may, under
certain circumstances, present protease-digested antigen fragments to already primed T cells,
thereby enhancing the ongoing immune response. HLA-DR^ keratinocytes also may be a target for
certain cytotoxic effector T cells. Cytokines such as IL-1, IL-6, and GM-CSF released from acti-
vated keratinocytes can stimulate activation and proliferation of T cells and, in the case of GM-
CSF, Langerhans cells. Monocytes and mast cells also may be activated and may release proin-
flammatory mediators. Spongiosis, cell injury, and cell death are the combined effect of these
interactions, and the clinical picture of allergic contact dermatitis results.
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UV-induced non-Langerhans cells, which downregu-
late immune responses. Non-Langerhans antigen-pre-
senting cells may function as a negative feedback
mechanism downregulating the hypersensitivity reac-
tion. This hypothesis currently is under investigation.
Keratinocytes in allergic and irritant skin reactions
express both ICAM-1 and HLA-DR. These immuno-
competent surface molecules are probably induced by
lymphokines such as gamma-interferon released from
local T cells.2'''̂ '-<'2<'9-̂ ' HLA-DR+ keratinocytes are,
under certain circumstances, able to present antigenic
peptide fragments to primed (memory) T cells.'^ Ad-
ditionally, HLA-DR^ keratinocytes can also act as tar-
gets for MHC class II restricted cytotoxic T-cell
clones.̂ ^ Thus, HLA-DR expression may allow kera-
tinocytes to participate in immunologic responses,
such as antigen presentation and cytotoxicity, that re-
sult in enhancement of the immune reaction. How-
ever, HLA-DR"^ keratinocytes may also be involved in
the development of antigen-specific tolerance. This
aspect of HLA-DR^ keratinocytes is discussed in an
upcoming section.
Regulation of the Inflammatory Response
in Allergic Contact Dermatitis
Multiple cell types, factors, and cytokines are involved
in regulation of the inflammatory response in allergic
contact dermatitis. Inhibitory and stimulatory factors
interact to determine whether the immune response is
up- or downregulated (Fig. 4). Normally, stimulatory
signals provided by Langerhans cells are counteracted
by inhibitory signals provided by keratinocytes such
that an immune response is not initiated. Antigens or
irritants can upset this balance, resulting in the devel-
opment of contact dermatitis.
Sensitization results in antigen-specific activation
of both effector and suppressor pathways. The net ef-
fect is dependent on the physical and chemical proper-




Figure 4. Mechanisms involved in epidermal immune response regulation. Multiple faetors and
mechanisms are responsible for immune regulation in the skin. Langerhans cells (LC) provide
positive signals for T-cell activation; other nonresident antigen-presenting cells present in in-
flammed skin may enhance this signal. Keratinocytes capable of releasing T-cell stimulatory
cytokines such as lL-1, IL-6, and GM-CSF also may function lo enhance the immune response.
Although the alloantigen-presenting capacity of HLA-DR+ keratinocytes is weak, the keratinocytes
can, under certain circumstances, present antigens leading to T-cell activation and possibly also
lymphokine release, and thus potentiate an ongoing immune response. On the other hand, the
epidermis also contains the capacity to downregulate the immune response. UV-induced non-
Langerhans CDl OKM5^DR* antigen-presenting cells seem to preferentially activate suppressor
pathways. Furthermore, HLA-DR+ keratinocytes can present antigen to unprimed T cells, result-
ing in antigen-specific tolerance to subsequent antigen presentation by Langerhans cells. A variety
of T-cell inhibitory cytokines may be released from keratinocytes in vitro including KLIF, PGE2,
TGF-beta, and ELDIF. The mechanism responsible for regulation of the release of stimulatory and
inhibitory cytokines from the keratinocytes is unknown. In the murine system, IJ* antigen-present-
ing cells (APC) and Thy 1 * dendritic T cells also contain the capability to downregulate immune
responses. Clear human analogues to the two murine cell types, however, await identification.
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Figure 5. Proposed model for the immunopathogenesis of irritant contact dermatitis. Irritants or
injury may trigger keratinocytes to release ehemoattractant factors such as eieosanoids, which may
recruit T cells (T) and macrophages (M0), and cytokines such as IL-1, IL-6, and GM-CSF. which
may assist T-cell and macrophage activation. Eieosanoids are potent T-cell chemoattractants. IL-1
may enhance antigen-independent activation of the recruited T cells in conjunction with IL-6 and
GM-CSF. Gamma-IFN and other lymphokines released from activated T cells can activate macro-
phages to release monokines, and can induce the expression of ICAM-1 on keratinocytes (K) and
endothelial cells (E). IL-3 released from activated T cells can induce mast cell (MC) proliferation;
monokines can cause mast cell degranulation augmenting the inflammatory reaction. lCAM-1 is
the natural Iigand for LFA-1, a molecule expressed on many leukocytes; therefore, increased
ICAM-1 expression is thought to enhance trapping of immunocompetent cells in the area. Cyto-
kines and factors released from the immunoeompetent eells cause inflammation and result in the
clinical picture of irritant contact dermatitis.
LFA-1
ICAM-1
tion. High concentrations of antigen induce antigen-
specific unresponsiveness through activation of
antigen-specific suppression. This suppression is trans-
ferrable through donor T lymphocytes to syngeneic
recipients.'^ Activation of antigen-specific suppressor
T ceils in this system may be due to systemic antigen
absorption following overloading of the skin by anti-
gen, thus bypassing epidermal Langerhans cells. As
mentioned earlier, antigen administration that by-
passes the Langerhans cells results in the activation of
antigen-specific suppressor T cells, which can down-
regulate the immune response.̂ "'̂ **'̂ ^ This mechanism
also may be responsible for the relative rarity df con-
tact dermatitis in workers exposed to large allergen
doses, such as nickel workers. It has also been used by
Kligman and others to treat patients with poison ivy
dermatitis with oral urushiol extract. ̂ "̂  However, uru-
shiol extract desensitization is short-lived and the side
effects are troublesome.
The type of antigen is also important in sensitiza-
tion. For example, application to the skin of 2,4-dini-
trothiocyanatebenzene (DNTB), an antigen that cross-
reacts with 2,4-dinitrofluorobenzene (DNFB), results
in suppressor T-cell activation that downregulates sub-
sequent reactions to DNFB.'̂ ''**
As mentioned earlier, cytokines released from ac-
tivated T cells induce keratinocyte HLA-DR expres-
sion, which may allow them to enhance the immune
reaction. Presentation of antigen by HLA-DR^ kera-
tinocytes to unprimed T cells, however, results in the
development of antigen-specific unresponsiveness to
later antigen presentation by Langerhans cells. Thus,
HLA-DR^ keratinocytes also may downregulate the
inflammatory response (Fig. 4).^''
Cytokines derived from keratinocytes can exert in-
hibitory or stimulatory effects on T cells, and their
balance may be a critical factor determining T-cell ac-
tivation state. Keratinocyte factors that downregulate
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T-cell responses include prostaglandins,**" eicosa-
noids,'^ epidermal cell-derived lymphocyte differen-
tiation inhibiting factor (ELDIF),'° keratinocyte lym-
phocyte inhibitor factor (KLIF),'^ and transforming
growth factor-beta (TGF-beta) (Fig. 4).'^
Bone marrow-derived cells capable of providing
downregulating signals also exist within the epidermis.
In the murine system, Granstein has demonstrated an
IJ^, UV-resistant, antigen-presenting cell type that ac-
tivates suppressor T-cell pathways (Fig. 4). '̂'̂ ^ Another
bone marrow-derived dendritic cell type distinct from
Langerhans cells also is constitutively present in mu-
rine epidermis.'̂ '̂̂ ^^ These cells lack class II MHC mol-
ecules but express Thy-1 and T-cell receptors com-
posed of gamma and delta chains.**̂ "**"* Thy 1̂  dendritic
intraepidermal gamma/delta T-cell receptor-positive
cells exert a negative effect on the immune response,
resulting in the induction of antigen-specific tolerance
(Fig. 4).̂ °
Despite intensive research, clear human analogues
to these cell types have not been found. However, bone
marrow-derived, non-Langerhans, antigen-presenting
cells do appear in the course of a contact dermatitis
reaction and may be involved in suppressor T-cell ac-
tivation.''̂ *'** This hypothesis is supported by the obser-
vation that these non-Langerhans cells demonstrate
the OKMrOKM5"^ phenotype.*"** This phenotype is
analogous to a minor (<5%) subset of blood mono-
cytes uniquely capable of activating autoreactive im-
munoregulatory T cells capable of immune downregu-
lation."-"
Pathogenic Mechanism of Irritant Contact
Dermatitis
Allergic and irritant dermatitis share many clinical and
histopathologic features and are often difficult to dis-
tinguish; however, clear differences exist. For example,
although both responses are characterized by a similar
distribution of T-cell subsets, the number of CDl^
Langerhans cells is decreased in irritant reactions,
whereas it is increased in allergic reactions.'''*''''**'^''
These findings are highlighted by our observation of
decreased epidermal antigen-presenting cell capacity
to activate T cells following irritant challenge and in-
creased epidermal antigen-presenting cell function fol-
lowing allergic challenge.'''''**
While allergic contact dermatitis is a classic exam-
ple of antigen-dependent T-cell activation, the patho-
genic mechanism of irritant contact dermatitis is not
known. We think, however, that the decreased capac-
ity of irritant-challenged epidermis to activate T cells
suggests that antigen-dependent pathways are not criti-
cal for the immunologic response in irritant contact
dermatitis. Thus, we propose that in irritant contact
dermatitis, cytokines released from mechanically or
chemically injured keratinocytes induce T-cell activa-
tion independent of antigen (Fig. 5), and that the ini-
tiating event in irritant-induced contact dermatitis is
unknown but may be the release of eicosanoids or
other chemoattractants by injured keratinocytes.
This hypothesis is supported by the observation
that epidermally derived chemoattractants and T-cell
growth enhancing factors are present in irritant skin
reactions."'^" Following T-cell activation and lympho-
kine release, the cellular immunologic event and the
regulation of the inflammatory response in both aller-
gic and irritant contact dermatitis seem to be similar.
Mechanism of Action of Therapeutic
Agents in the Treatment of Contact
Dermatitis
Cortioosteroids
Corticosteroids have a profound effect on the immune
system. Topically, they inhibit both the afferent and
the efferent limb of the allergic contact dermatitis reac-
tion.''^'"' Steroids inhibit antigen-specific lymphocyte
activation and proliferation.'' This is probably due to
direct effect on both antigen-presenting cells and
T cells. Topical application of steroids to the skin
depletes Langerhans cells of CDl and HLA-DR
molecules, abrogating their antigen-presenting func-
tion.""*-'™ Corticosteroids also block T-cell release of
IL-2, thereby inhibiting T-cell proliferation."*' These
immunomodulatory effects turn off the ongoing im-
mune response in contact dermatitis and are responsi-
ble for the therapeutic effects of corticosteroids in the
treatment of contact dermatitis.
Ultraviolet Radiation
Ultraviolet light also exerts its therapeutic effects on
contact dermatitis through the immune system. Ultra-
violet exposure of the skin abrogates Langerhans cell
function and induces the appearance of bone marrow-
derived antigen-presenting cells, which can activate T
suppressor cells.
Ultraviolet exposure of the skin results in the dis-
appearance of Langerhans cell surface molecules (CD 1
and HLA-DR), and thus eliminates their antigen-pres-
enting function (Fig. e).""'"^ However, HLA-DR"*̂ ,
bone marrow-derived, antigen-presenting melano-
phages appear in the epidermis in response to the irra-
diation.'"^"""" These non-Langerhans antigen-present-
ing cells (non-LC APC) are ultrastructurally distinct
from Langerhans cells in that they lack Birbeck's gran-
ules and express melanosomes within phagolysosomes.







Figure 6. Ultraviolet irradiation of the skin induces activation of
suppressor T-cell pathways. Ultraviolet (UV) irradiation of the skin
abrogates the function of Langerhans cells (LC) and induces the
appearance of an epidermal non-Langerhans cell antigen-presenting
cell (non-LC APC) type. This UV-induced non-Langerhans cell an-
tigen-presenting cell is distinct from Langerhans eells in that it lacks
Birbeck granules and the CDl determinant. When Langerhans cells
present antigen to T lymphocytes, the activation of effector T lym-
phocytes and upregulation of the immune response is the result. In
contrast, when non-Langerhans antigen-presenting cells present an-
tigen, the T-suppressor lymphocytes are activated, resulting in
downregulation of the immune response.
Phenotypically, they lack the CDl determinant ex-
pressed on epidermal Langerhans cells and bear the
OKM1^OKM5^ phenotype, demonstrating analogy to
a minor subpopulation of antigen-presenting cells in
the blood'' that can activate immunoregulatory T
cells.̂ -' These non-LC APC are capable of activating
both antigen-specific CD4+2H4" T cells, which pro-
vide help for B-cell immunoglobulin production, as
well as autoreactive CD4^2H4^ T cells, which induce
the maturation of suppressor T cells.'°^'""' However,
CD4"̂ 2H4"*̂  suppressor/inducer T-cell activation domi-
nates, and the net functional effect is therefore the in-
duction of suppression (Fig. 6).'°'"°
In the murine system, sensitization through skin
previously exposed to low doses of UV radiation re-
sults in antigen-specific unresponsiveness. This local
effect is due to the appearance of antigen specific T
suppressor cells that operate at the afferent limb of the
immune response to prevent the activation of effector
cells for delayed-type hypersensitivity.''' High doses of
UV radiation, however, result in systemic suppression
of the immune response, where sensitization through
either exposed or unexposed skin results in induction
of antigen-specific tolerance.̂ **"^ Although the cellular
mechanisms responsible for induction of these sup-
pressor T cells are not clear, UV-resistant, IJ-restricted,
antigen-presenting cells or Thyl^ dendritic epidermal
cells that express gamma-delta T-cell receptors may be
important. 81.82.90 Ultraviolet-induced epidermal
CDl OKM5^DR+, non-Langerhans, antigen-present-
ing cells of the human system may be the functional
analogue to epidermal cells in the murine system that
provide antigen-specific downregulating signals.
Cyclosporine A
Cyclosporine A is a cyclic undecapeptide that causes
suppression of immune stimulation both in vivo and in
vitro. Systemic cyclosporine A is very efficient in the
treatment of psoriasis and will probably demonstrate
efficacy in all skin diseases dependent on activated T
cells. "^ Cyclosporine A has differential effects on T
lymphocyte subsets. Helper-inducer T cells are sensi-
tive to very low doses of cyclosporine A, and decreased
production of lymphokines such as IL-2, IL-4,
gamma-interferon, and tumor necrosis factor re-
sults.'"*""^ The maturation and generation of cyto-
toxic T cells are also affected by low doses cyclosporine
A.'" In contrast, suppressor T cells are insensitive to
low doses of cyclosporine A."'*'"*
These immunologic effects indicate that cyclo-
sporine A may be useful in the treatment of contact
dermatitis. Accordingly, animal studies have demon-
strated that systemic cyclosporine A blocks the effector
function of delayed-type hypersensitivity T cells, al-
though the priming of these cells is cyclosporine A-in-
sensitive."' Topical cyclosporine A inhibits the elicita-
tion of contact hypersensitivity in guinea pigs.''° How-
ever, application of topical cyclosporine A to human
skin has only minimal effect, probably due to either
lack of absorption or epidermal/dermal inactivation of
the drug.'"' Systemic cyclosporine A may play a role in
the treatment of severe recalcitrant contact dermatitis;
however, due to its nephrotoxicity, widespread use of
this agent in contact dermatitis awaits an efficient topi-
cal formulation.
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